AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18391094 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation group
Number of subjects: 4736
Study 15925877 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial urokinase
Number of subjects: 16
Study 15925877 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 12866040 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin exclusively
Number of subjects: 27290
Study 12866040 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-aspirin NSAIDs exclusively (e.g., ibuprofen)
Number of subjects: 27290
Study 12866040 — intervention group
Group type: EXPERIMENTAL
Intervention: Both aspirin and non-aspirin NSAIDs
Number of subjects: 27290
Study 12866040 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis diagnosis
Number of subjects: 27290
Study 12866040 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoarthritis diagnosis
Number of subjects: 27290
Study 12866040 — intervention group
Group type: COMPARATOR
Intervention: No use of aspirin or other non-aspirin NSAIDs
Number of subjects: 27290
Study 10819336 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir (10 mg, inhaled, twice daily for 5 days)
Number of subjects: 471
Study 10819336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 471
Study 8887036 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin (GL) given intravenously at a dose of 40 ml (0.2% solution) daily for 4 consecutive weeks.
Number of subjects: 17
Study 8887036 — intervention group
Group type: COMPARATOR
Intervention: Control group received only dental cleaning.
Number of subjects: 17
Study 2058066 — intervention group
Group type: EXPERIMENTAL
Intervention: KLH
Number of subjects: 42
Study 2058066 — intervention group
Group type: COMPARATOR
Intervention: BCG
Number of subjects: 42
Study 6644525 — intervention group
Group type: EXPERIMENTAL
Intervention: Faschingbauer Abbreviated MMPI (FAM)
Number of subjects: 514
Study 6644525 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPI‐168
Number of subjects: 514
Study 6644525 — intervention group
Group type: COMPARATOR
Intervention: Full Minnesota Multiphasic Personality Inventory (MMPI)
Number of subjects: 514
Study 30795736 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of Attitudes towards guidelines scale
Number of subjects: 768
Study 29061547 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiger‐II catheter
Number of subjects: 320
Study 29061547 — intervention group
Group type: COMPARATOR
Intervention: Judkins catheter
Number of subjects: 320
Study 27880804 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary intervention in a community-based obesity programme
Number of subjects: 239
Study 24858506 — intervention group
Group type: EXPERIMENTAL
Intervention: Forest therapy (viewing a real forest landscape for 15 min)
Number of subjects: 98
Study 24858506 — intervention group
Group type: COMPARATOR
Intervention: Urban area viewing (control group, viewing urban area for 15 min)
Number of subjects: 98
Study 22578980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mate tea (MT)
Number of subjects: 74
Study 22578980 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (DI)
Number of subjects: 74
Study 22578980 — intervention group
Group type: EXPERIMENTAL
Intervention: Mate tea with dietary intervention (MD)
Number of subjects: 74
Study 22578980 — intervention group
Group type: COMPARATOR
Intervention: Control (DI and MD)
Number of subjects: 74
Study 19853510 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide 25 mg on days 1-21 plus dexamethasone 40 mg on days 1-4, 9-12, and 17-20 of a 28-day cycle (high dose)
Number of subjects: 445
Study 19853510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg on days 1-21 plus dexamethasone 40 mg on days 1, 8, 15, and 22 of a 28-day cycle (low dose)
Number of subjects: 445
Study 19853510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dexamethasone group
Number of subjects: 445
Study 19853510 — intervention group
Group type: COMPARATOR
Intervention: High-dose dexamethasone group
Number of subjects: 445
Study 19853510 — intervention group
Group type: COMPARATOR
Intervention: High-dose regimen
Number of subjects: 445
Study 19853510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose regimen
Number of subjects: 445
Study 17699177 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy
Number of subjects: 0
Study 17699177 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillators
Number of subjects: 0
Study 16197655 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (50 mg/day increasing to 100 mg/day after 1 week)
Number of subjects: 70
Study 16197655 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 70
Study 14499730 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and heparin
Number of subjects: 0
Study 14499730 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study 10440426 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 12
Study 10440426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8707167 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg)
Number of subjects: 959
Study 8707167 — intervention group
Group type: COMPARATOR
Intervention: Standard unfractionated heparin (Ca-heparin, 3 x 5,000 U)
Number of subjects: 959
Study 1867903 — intervention group
Group type: EXPERIMENTAL
Intervention: Contract condition with co-worker-delivered reminders, prompting at least once a month for six months, plus mailed prompts monthly.
Number of subjects: 36
Study 1867903 — intervention group
Group type: COMPARATOR
Intervention: Control condition with mailed prompts monthly.
Number of subjects: 36
Study 6284597 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivanol (6,9‐diamino‐2‐oxyethyl acridine lactate) during elective midtrimester abortions
Number of subjects: 0
Study 6284597 — intervention group
Group type: COMPARATOR
Intervention: Rivanol (6,9‐diamino‐2‐oxyethyl acridine lactate) in women with fetal death
Number of subjects: 0
Study 31151456 — intervention group
Group type: EXPERIMENTAL
Intervention: CBL-based CAFA
Number of subjects: 389
Study 31151456 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-CBL CAFA)
Number of subjects: 389
Study 28703621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued budget categories (attention directed to one side of the screen)
Number of subjects: 0
Study 28703621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued attention (manipulated through spatial cuing)
Number of subjects: 0
Study 28703621 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual attention and mental attention (orthogonally manipulated)
Number of subjects: 0
Study 28703621 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued categories (attention increased prioritization)
Number of subjects: 0
Study 25647757 — intervention group
Group type: EXPERIMENTAL
Intervention: R-L+ stimulation (anodal stimulation of left PPC)
Number of subjects: 12
Study 25647757 — intervention group
Group type: COMPARATOR
Intervention: R+L- stimulation (anodal stimulation of right PPC)
Number of subjects: 12
Study 25647757 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study 25443069 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 144
Study 25443069 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 144
Study 22582197 — intervention group
Group type: EXPERIMENTAL
Intervention: Euhydrated condition
Number of subjects: 19
Study 22582197 — intervention group
Group type: COMPARATOR
Intervention: Hypohydrated condition
Number of subjects: 19
Study 22582197 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 19
Study 19683119 — intervention group
Group type: EXPERIMENTAL
Intervention: Rusch ViewMax
Number of subjects: 26
Study 19683119 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 26
Study 17577847 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Stenting (DS)
Number of subjects: 300
Study 17577847 — intervention group
Group type: COMPARATOR
Intervention: Conventional Stenting (CS)
Number of subjects: 300
Study 10990103 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral plus parenteral nutrition (treatment group)
Number of subjects: 120
Study 10990103 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutrition plus placebo (placebo group)
Number of subjects: 120
Study 8741021 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (240 mg daily)
Number of subjects: 216
Study 8741021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 1331493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 200 mg kg‐1
Number of subjects: 9
Study 1331493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 300 mg kg‐1
Number of subjects: 9
Study 1331493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 400 mg kg‐1
Number of subjects: 9
Study 1331493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 500 mg kg‐1
Number of subjects: 9
Study 1331493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate 100 mg kg‐1
Number of subjects: 9
Study 1331493 — intervention group
Group type: COMPARATOR
Intervention: Placebo (CaCO3 500 mg kg‐1)
Number of subjects: 9
Study 4019271 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed 252Cf implant therapy
Number of subjects: 82
Study 4019271 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 82
Study 4019271 — intervention group
Group type: EXPERIMENTAL
Intervention: Early 252Cf implant therapy
Number of subjects: 82
Study 31115845 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in the SELECT BC trial receiving either S-1 or taxane as first-line treatment.
Number of subjects: 0
Study 31115845 — intervention group
Group type: COMPARATOR
Intervention: Non-participants who declined to participate in the SELECT BC trial.
Number of subjects: 0
Study 31115845 — intervention group
Group type: COMPARATOR
Intervention: Non-participants who received the same chemotherapy (S-1 or taxane) after declining participation.
Number of subjects: 0
Study 30439808 — intervention group
Group type: EXPERIMENTAL
Intervention: Watery eye
Number of subjects: 210
Study 30439808 — intervention group
Group type: COMPARATOR
Intervention: Cataract eye
Number of subjects: 210
Study 30439808 — intervention group
Group type: COMPARATOR
Intervention: Macular region pathology
Number of subjects: 210
Study 26636418 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐3074 1 mL (2.275 mg) applied to the scalp once a day (o.d.)
Number of subjects: 50
Study 26636418 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐3074 1 mL (2.275 mg) applied to the scalp twice a day (b.i.d.)
Number of subjects: 50
Study 26636418 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral tablet of finasteride once a day (o.d.)
Number of subjects: 50
Study 26636418 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐3074 100 μL applied o.d.
Number of subjects: 50
Study 26636418 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐3074 200 μL applied o.d.
Number of subjects: 50
Study 26636418 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐3074 300 μL applied o.d.
Number of subjects: 50
Study 26636418 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐3074 400 μL applied o.d.
Number of subjects: 50
Study 26636418 — intervention group
Group type: COMPARATOR
Intervention: Vehicle applied o.d.
Number of subjects: 50
Study 26636418 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 50
Study 24484178 — intervention group
Group type: EXPERIMENTAL
Intervention: rF-B7.1 or rF-TRICOM (3.7×10(7) or 3.7×10(8) plaque-forming units) administered by intralesional injection every 4 weeks
Number of subjects: 12
Study 24484178 — intervention group
Group type: EXPERIMENTAL
Intervention: rF-B7.1 or rF-TRICOM
Number of subjects: 12
Study 23100396 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of 1, 1-2, 1-3, ..., 1-10 serial skip sections of 3-mm punch biopsies
Number of subjects: 90
Study 23100396 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimating 95% confidence intervals (CIs) of ENFs/mm
Number of subjects: 90
Study 23100396 — intervention group
Group type: EXPERIMENTAL
Intervention: New continuous measure combining nerve conduction and ENFs/mm
Number of subjects: 90
Study 19857185 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic cancer vaccines (various types including antigen-presenting-cell-based, vector-based, and whole tumor cell vaccines)
Number of subjects: 0
Study 18834274 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnic/racial minority patients (American Indian, African American, Hispanic, Asian)
Number of subjects: 269
Study 18834274 — intervention group
Group type: COMPARATOR
Intervention: Whites
Number of subjects: 269
Study 16094110 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lysine-aspirin (16 mg every 48 hours for 6 months)
Number of subjects: 11
Study 16094110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 12173902 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary infarct intervention in octogenarians (1997-1998)
Number of subjects: 40
Study 12173902 — intervention group
Group type: COMPARATOR
Intervention: Younger patients (<80 years) treated with primary infarct intervention (1997-1998)
Number of subjects: 40
Study 12173902 — intervention group
Group type: COMPARATOR
Intervention: Octogenarians treated in 1991-1994
Number of subjects: 40
Study 10599182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (80 mg)
Number of subjects: 10
Study 10599182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7564036 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (anticoagulant) alone for 21 days
Number of subjects: 24
Study 7564036 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (200 mg/day)
Number of subjects: 24
Study 7564036 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg/day)
Number of subjects: 24
Study 7564036 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of anticoagulants and antiplatelet agents
Number of subjects: 24
Study 1793024 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold treatment
Number of subjects: 44
Study 1793024 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 44
Study 1793024 — intervention group
Group type: EXPERIMENTAL
Intervention: Both gold and MTX treatment
Number of subjects: 44
Study 1793024 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved group (overall)
Number of subjects: 44
Study 1793024 — intervention group
Group type: EXPERIMENTAL
Intervention: Unimproved group (overall)
Number of subjects: 44
Study 31782786 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glucocorticoids (GCs) and cyclophosphamide (CYC)
Number of subjects: 733
Study 31782786 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (GCs) only
Number of subjects: 733
Study 31782786 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥65 years
Number of subjects: 733
Study 31782786 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary involvement
Number of subjects: 733
Study 31782786 — intervention group
Group type: EXPERIMENTAL
Intervention: Five Factor Score ≥1
Number of subjects: 733
Study 31782786 — intervention group
Group type: EXPERIMENTAL
Intervention: Occurrence of severe infections (SI)
Number of subjects: 733
Study 31474526 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care practitioner counseling on medication disposal
Number of subjects: 400
Study 31474526 — intervention group
Group type: COMPARATOR
Intervention: No counseling (control group)
Number of subjects: 400
Study 28209450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TA)
Number of subjects: 80
Study 28209450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 25933204 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over dominant M1 at least 40 mins before task performance (Experiment 1)
Number of subjects: 52
Study 25933204 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS directly before task performance (Experiment 2)
Number of subjects: 52
Study 25933204 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS during task performance (Experiment 3)
Number of subjects: 52
Study 25933204 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 52
Study 22926533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen pressure injection (OPI) device during MAL‐PDT
Number of subjects: 0
Study 22926533 — intervention group
Group type: COMPARATOR
Intervention: Standard MAL‐PDT without OPI
Number of subjects: 0
Study 21317618 — intervention group
Group type: EXPERIMENTAL
Intervention: E-OA-07
Number of subjects: 0
Study 21317618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20234119 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored genetic counseling (CTGC)
Number of subjects: 0
Study 20234119 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard genetic counseling (SGC)
Number of subjects: 0
Study 20234119 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counseling participants
Number of subjects: 0
Study 20234119 — intervention group
Group type: EXPERIMENTAL
Intervention: Test result acceptors
Number of subjects: 0
Study 20234119 — intervention group
Group type: COMPARATOR
Intervention: Cancer history
Number of subjects: 0
Study 20234119 — intervention group
Group type: COMPARATOR
Intervention: BRCA1/2 prior probability
Number of subjects: 0
Study 17699970 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 ml spacer with valve
Number of subjects: 150
Study 17699970 — intervention group
Group type: EXPERIMENTAL
Intervention: 165 ml spacer with valve
Number of subjects: 150
Study 17699970 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ml spacer without valve
Number of subjects: 150
Study 17699970 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 ml indigenously made spacer without valve
Number of subjects: 150
Study 17699970 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml indigenously made spacer without valve
Number of subjects: 150
Study 15601653 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous quinine followed by oral Malarone
Number of subjects: 360
Study 15601653 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine followed by oral quinine
Number of subjects: 360
Study 12161054 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including didactic training and computerized compliance feedback for diabetes management.
Number of subjects: 0
Study 12161054 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) during the same period.
Number of subjects: 0
Study 10214498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartoon message about safe sex
Number of subjects: 0
Study 10214498 — intervention group
Group type: EXPERIMENTAL
Intervention: Written message about safe sex
Number of subjects: 0
Study 10214498 — intervention group
Group type: COMPARATOR
Intervention: Both messages (cartoon and written)
Number of subjects: 0
Study 7783024 — intervention group
Group type: EXPERIMENTAL
Intervention: Bair Hugger forced‐warm air warming blanket
Number of subjects: 32
Study 7783024 — intervention group
Group type: COMPARATOR
Intervention: Blanketrol water coil‐heated hypothermia blanket
Number of subjects: 32
Study 2191586 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone + altizide (S/A)
Number of subjects: 186
Study 2191586 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (control)
Number of subjects: 186
Study 6775518 — intervention group
Group type: EXPERIMENTAL
Intervention: High nitrogen (N) intravenous nutritional regimen
Number of subjects: 0
Study 6775518 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric regimen containing no amino acids
Number of subjects: 0
Study 6775518 — intervention group
Group type: EXPERIMENTAL
Intervention: High nitrogen group
Number of subjects: 0
Study 6775518 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (high nitrogen and isocaloric)
Number of subjects: 0
Study 31834166 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week HiBalance group training (n = 61)
Number of subjects: 117
Study 31834166 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 56)
Number of subjects: 117
Study 31239099 — intervention group
Group type: EXPERIMENTAL
Intervention: Taijia (generic clopidogrel)
Number of subjects: 128
Study 31239099 — intervention group
Group type: COMPARATOR
Intervention: Plavix® (reference clopidogrel)
Number of subjects: 128
Study 26969422 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional (two-piece) brackets
Number of subjects: 46
Study 26969422 — intervention group
Group type: COMPARATOR
Intervention: Metal injection moulding (MIM) brackets
Number of subjects: 46
Study 25499208 — intervention group
Group type: EXPERIMENTAL
Intervention: SPORT surgical cohort
Number of subjects: 6846
Study 25499208 — intervention group
Group type: COMPARATOR
Intervention: NSQIP cohort
Number of subjects: 6846
Study 25499208 — intervention group
Group type: COMPARATOR
Intervention: SPORT nonoperative group
Number of subjects: 6846
Study 22421017 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acid (PUFA) group
Number of subjects: 98
Study 22421017 — intervention group
Group type: COMPARATOR
Intervention: Traditional PN support
Number of subjects: 98
Study 20499117 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvano-formed crowns (GC)
Number of subjects: 48
Study 20499117 — intervention group
Group type: COMPARATOR
Intervention: Metal-ceramic crowns (MC)
Number of subjects: 48
Study 19074978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment focusing solely on eating disorder features
Number of subjects: 154
Study 19074978 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex cognitive-behavioral treatment addressing mood intolerance, clinical perfectionism, low self-esteem, or interpersonal difficulties
Number of subjects: 154
Study 19074978 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition (8-week period before treatment)
Number of subjects: 154
Study 16719653 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive interference (PI) adaptation
Number of subjects: 0